NR4A1 and osteoporosis: Endocrine therapy is a standard treatment for hormone receptor-positive breast cancer and is associated with a significant reduction in disease recurrence and improvement in overall survival [27], but endocrine therapy is also associated with an increased risk of osteoporosis and osteoporotic fracture, particularly among patients receiving AI therapy [28].